Insiders · AKTS

Ansbert Gadicke

10% owner at Aktis Oncology, Inc. (AKTS) since January 2026

Ansbert Gadicke has filed 70 insider reports with the SEC since March 2021, as 10% owner at Aktis Oncology, Inc. (AKTS), former 10% Owner at Werewolf Therapeutics, Inc. (HOWL) and former 10% Owner at iTeos Therapeutics, Inc. (ITOS) and at 5 more companies. In the last 12 months Ansbert Gadicke bought $20M and sold $363K of stock on the open market. In the latest filing, on January 14, 2026, Ansbert Gadicke bought 1,112,777 shares of Aktis Oncology, Inc. (AKTS) for $20M at an average of $18.00.

Filings
70
Companies
8
Bought on market
$23.9M
Sold on market
$128M

Companies where Ansbert Gadicke is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Aktis Oncology, Inc. logo
AKTS
Aktis Oncology, Inc.
10% ownersince January 2026$20M$18.00$16.15-10%Jan 14, 2026
Werewolf Therapeutics, Inc. logo
HOWL
Werewolf Therapeutics, Inc.
Former 10% Owner$3.92M$2.09M$16.00$0.9466-94%Dec 4, 2025
iTeos Therapeutics, Inc. logo
ITOS
iTeos Therapeutics, Inc.
Former 10% Owner$57.1MMay 15, 2025
Tcr2 Therapeutics Inc. logo
TCRR
Tcr2 Therapeutics Inc.
Director, 10% owner$132KJun 5, 2023
Cullinan Oncology, Inc. logo
CGEM
Cullinan Oncology, Inc.
10% owner595,489$8.85M$8.89Feb 10, 2023
Allovir, Inc. logo
KLRS
Allovir, Inc.
Director, 10% owner30,197$1.28Aug 1, 2022
Repare Therapeutics Inc. logo
RPTX
Repare Therapeutics Inc.
10% owner$42.5MJul 13, 2021
Harpoon Therapeutics, Inc. logo
HARP
Harpoon Therapeutics, Inc.
10% owner$17.1MJun 2, 2021

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.

Every filing

Also sits on boards with

Officers and directors who share two or more companies with Ansbert Gadicke.

Compare Ansbert Gadicke with

Other insiders at the same companies

Questions about Ansbert Gadicke

What is Ansbert Gadicke's role at Aktis Oncology, Inc.?
Ansbert Gadicke reports to the SEC as 10% owner at Aktis Oncology, Inc. (AKTS), according to the latest filing on January 14, 2026. Ansbert Gadicke has also filed as former 10% Owner at Werewolf Therapeutics, Inc. (HOWL), former 10% Owner at iTeos Therapeutics, Inc. (ITOS), director and 10% owner at Tcr2 Therapeutics Inc. (TCRR) and 10% owner at Cullinan Oncology, Inc. (CGEM).
How many shares does Ansbert Gadicke own?
After the latest filing that states it, Ansbert Gadicke directly owned 595,489 shares of Cullinan Oncology, Inc. (CGEM) and 30,197 shares of Allovir, Inc. (KLRS). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Ansbert Gadicke bought or sold stock recently?
The most recent open-market purchase was on January 12, 2026: bought 1,112,777 shares of Aktis Oncology, Inc. (AKTS) for $20M at an average of $18.00. The most recent open-market sale was on December 4, 2025: sold 199,732 shares of Werewolf Therapeutics, Inc. (HOWL) for $183K at an average of $0.92.
How do I get alerts when Ansbert Gadicke files?
Follow Ansbert Gadicke on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Ansbert Gadicke (SEC CIK 0001134655). Totals count each trade once, skipping amendments whose original is on file, from Mar 15, 2021 on. View on SEC EDGAR · Get this as JSON